insights.citeline.com
Exelixis’s novel kinase inhibitor zanzalintinib has shown promise in a metastatic colorectal cancer population but some experts want to see more data before passing judgement on whether it can become a new chemotherapy-free treatment option for these patients.
about 2 months ago